A Phase II Study of Low Dose Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer

Trial Profile

A Phase II Study of Low Dose Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Algenpantucel-L (Primary) ; Antineoplastics
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 30 May 2014 Planned End Date changed from 1 Sep 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 07 Aug 2013 Result were presented at ASCO 2013, according to a NewLink Genetics Corporation media release.
    • 20 Sep 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top